Opthea’S Wet AMD Program Featured At Ophthalmology Events

Ophthalmology Innovation Summit XIV, November 23, 2024

MELBOURNE, Australia, and PRINCETON, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT,“Opthea”, the“Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that Opthea and sozinibercept will be highlighted during two upcoming Ophthalmology conferences.

Conference details are as follows:

The 17 th Congress of the Asia-Pacific Vitreo-Retina Society (APVRS)

Gregg T. Kokame, MD, MMM, FASRS, will present data from a predefined subgroup of the sozinibercept Phase 2b wet AMD trial related to patients with polypoidal choroidal vasculopathy (PCV), measured at 24 weeks. Data from this subgroup show that patients treated with a combination of sozinibercept and ranibizumab experienced significantly better visual and anatomic outcomes compared to ranibizumab alone.

APVRS, themed Transforming Retinal Disease Management with Technology, gathers a distinguished international faculty of top specialists in vitreo-retina to share their expertise and experience. The scientific program will focus on exciting areas such as novel surgical innovations
and therapies, and latest advances in imaging and research.

Ophthalmology Innovation Summit XIV (OIS)

The Ophthalmology Innovation Summit connects clinical, corporate, and capital leaders to drive the ophthalmic market forward. It showcases groundbreaking advancements and clinical insights in both anterior and posterior ophthalmology segments and offers the opportunity to learn, network and collaborate.

About Opthea

Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

Opthea's lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST, NCT04757636 , and ShORe, NCT04757610 ) for use in combination with standard-of-care anti-VEGF-A therapies to improve the overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents alone.

To learn more, visit our website at and follow us on X and LinkedIn .

Authorized for release to ASX by Frederic Guerard, PharmD, CEO

Investor Inquiries

PJ Kelleher
LifeSci Advisors, LLC
Email: ...
Phone: 617-430-7579

Media Inquiries

Silvana Guerci-Lena
NorthStream Global Partners
Email: ...

Join our email database to receive program updates:
Tel: +61 (0) 3 9826 0399, Email: ... Web:

Source: Opthea Limited

MENAFN12112024004107003653ID1108876061